Loading…
Fair Prescription Drug Competition Act
Legislative Progress
Introduced
February 26, 2009
Latest Action
February 26, 2009
Primary Sponsor
John D. Rockefeller, IVDemocratic(WV)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,048 other S bills in the 111th — cohort avg 29d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2011 · second_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization. Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · first_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · first_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act; Generating Antibiotic Incentives Now (GAIN Act)
Client expense: Not reported · Firm income: $35,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · first_quarter · Health Issues
H.R. 3590 The Patient Protection and Affordable Care Act - General Healh Care Coverage and Reimbursement; implementation issues. H.R. 6331 The Gain Act The Food and Drug Administration legislative and regulatory implementation issues. S.369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R. 573 and S. 501 Fair Prescription Drug Competition Act; Generating Antibiotic Incentive Now (GAIN Act) Pub. L. 111-148 Patient Protection and Affordable Care Act of 2010 Pub. L. 111-152 Health Care and Education Reconcilliation Act of 2010 Medical Research Antibiotic Resistance Issues Issues relating to antibiotic and antimicrobial resistance
Client expense: $320,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2011 · first_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization. Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
| Democratic |
| WI |
| Jeanne Shaheen | Democratic | NH |
| Patrick J. Leahy | Democratic | VT |
| Sherrod Brown | Democratic | OH |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2010 · fourth_quarter · Health Issues
Medical Research Antibiotic Resistance issues P.L. 111-148 Patient Protection and Affordable Care Act implementation P.L. 111-152 Health Car and Education Reconcilliation Act of 2010 implementation H.R. 6331 Generating Antibiotic Incentives Now Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S.11 To restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals H.R. 4994 Medicare and Medicaid Extenders Act of 2010; P.L.111-309 (340B provisions) H.R. 5712 The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286 (340B provisions) H.R. 759 Food and Drug Administration Globalization Act of 2009 S.882 The Drug and Device Accountability Act of 2009 H.R. 5740 To provide for the mandatory recall of adulterated or misbranded drugs S.369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R.573 Fair Prescription Drug Competition Act S.501 Fair Prescription Drug Competition Act Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) H.R. 4213 American Jobs and Closing Tax Loopholds Act of 2010
Client expense: $210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2010 · fourth_quarter · Copyright/Patent/Trademark
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 628, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings: false patent marking H.R. 5980, Bring Jobs Back to America: Strategic Manufacturing & Job Repatriation Act: publication of patent applications and the economy H.R. 6352, Patent Lawsuit Reform Act of 2010: false patent marking H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 299, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 1315, Drug Price Competition Act of 2009: 180-day exclusivity issues S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements International intellectual property policy issues Biopharmaceutical innovation policy issues
Client expense: $4,900,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting the 340B program including H.R. 4213, American Jobs and Closing Tax Loopholes Act Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Prescription drug advertising; and federal preemption for prescription drugs.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
Budget Reconcilliation, Implementation of Health Care Reform, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, 340B Drug Pricing Program, and generic drugs S.501 - Fair Prescription Drug Competition Act, all provisions S.882 - Drug and Device Accountability Act of 2009, Title I Subtitle A, B, C, and D and Title II H.R. 759 - Food and Drug Administration Globalization Act of 2009, Title II S.525, S.1232, and H.R.1298 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act, Title VII - Improving Access to Innovative Medical Therapies H.R.4872 - Reconciliation Bill, Section 1101, Closing the Medicare Prescription Drug "Donut Hole" H.R.4213 - American Jobs and Closing Tax Loopholes Act H.R.4899 - War Supplemental S.1315 - Drug Price Competition Act of 2009
Client expense: $342,888 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2010 · fourth_quarter · Budget/Appropriations
FY2011 Omnibus (Senate Only) Coburn Amendment #4697to S. 501
Client expense: Not reported · Firm income: $10,000
Government targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE, White House Office
2010 · fourth_quarter · Budget/Appropriations
FY2011 Omnibus - provisions related to PIRCS and early learning programs Coburn Amendment #4697to S. 501
Client expense: Not reported · Firm income: $10,000
Government targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2010 · fourth_quarter · Budget/Appropriations
FY2011 Omnibus Coburn Amendment #4697to S. 501
Client expense: Not reported · Firm income: Not reported
Government targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Food Industry (safety, labeling, etc.)
S. 501: FDA Food Safety and Modernization Act; provisions related to Title I, Improving Capacity to Prevent Food Safety Problems, Section 103: Harard Analysis and risk-based preventative controls.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Copyright/Patent/Trademark
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs; authorized generic drug provisions. H.R. 1260, Patent Reform Act of 2009; reforms of the patent laws. H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements. H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding. S. 369, Preserve Access to Affordable Generics Act: patent settlements. S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions. S. 515, Patent Reform Act of 2009: reforms of the patent laws. S. 610, Patent Reform Act of 2009: reforms of the patent laws.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Education
FY 2011 Labor, Health and Human Services and Education Appropriateions/ S.3686 FY 2011 Labor, Health and Human Services and Education appropriations bill: Parent information resource centers, early learning programs.; 1st Continuing Resolution, H. 3081; 2nd Continuing Resolution, HJRes 101; 3rd Continuing Resolution, HJRes 105; Continuing Appropriateions, H.3082; FY2011 Omnibus (Senate Only); Coburn Amendment #4697 to S. 501; Healthcare (Senate/House/HHS) - Monitor guidance ARRA funds.
Client expense: Not reported · Firm income: Not reported
Government targets: Education, Dept of, Health & Human Services, Dept of (HHS)
2010 · first_quarter · Insurance
Issues related to Fraternal's 501(c)(8) tax exempt status.
Client expense: Not reported · Firm income: Not reported
2010 · first_quarter · Health Issues
Issues related to Fraternal's 501(c)(8) tax exempt status.
Client expense: Not reported · Firm income: Not reported
2010 · first_quarter · Taxation/Internal Revenue Code
Issues related to Fraternal's 501(c)(8) tax exempt status.
Client expense: Not reported · Firm income: Not reported
2010 · first_quarter · Financial Institutions/Investments/Securities
Issues related to Fraternal's 501(c)(8) tax exempt status.
Client expense: Not reported · Firm income: Not reported
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $75,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 573 and S. 501, Fair Prescription Drug Competition Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting the 340B program including H.R. 4213, American Jobs and Closing Tax Loopholes Act Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Prescription drug advertising; and federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Medical Research Antibiotic Resistance issues P.L. 111-148 Patient Protection and Affordable Care Act (PPACA) - funding of PPACA programs and provisions P.L. 111-152 Health Care and Education Reconciliation Act of 2010 PDUFA Reauthorization - The Prescription Drug User Fee Act is due for reauthorization in 2012 and discussions in anticipation of that reauthorization have begun H.R. 5712 Health Care Technical Corrections - This bill would repeal a provision of the health care reform bill that would extend debarring to all parts of a corporate family when any part of that corporate family settles an investigation of misconduct with the government HR 759 Food and Drug Administration Globalization Act of 2009 S. 882 The Drug and Device Accountability Act of 2009 H.R.5740 - To provide for the mandatory recall of adulterated or misbranded drugs S. 369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R. 573 Fair Prescription Drug Competition Act S. 501 Fair Prescription Drug Competition Act H.R. 6331 Generating Antibiotic Incentives Now Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) - changes to the 340B Drug Discount Program. S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2010 · third_quarter · Copyright/Patent/Trademark
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements International intellectual property issues
Client expense: $5,180,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2010 · third_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
Budget Reconcilliation, Implementation of Health Care Reform, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Authorized Generics, Prescription Drug Importation/Re-Importation, 340B Drug Pricing Program, and generic drugs S.501 - Fair Prescription Drug Competition Act, all provisions S.882 - Drug and Device Accountability Act of 2009, Title I Subtitle A, B, C, and D and Title II H.R. 759 - Food and Drug Administration Globalization Act of 2009, Title II S.525, S.1232, and H.R.1298 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act, Title VII - Improving Access to Innovative Medical Therapies H.R.4872 - Reconciliation Bill, Section 1101, Closing the Medicare Prescription Drug "Donut Hole" H.R.4213 - American Jobs and Closing Tax Loopholes Act H.R.4899 - War Supplemental S.1315 - Drug Price Competition Act of 2009
Client expense: $372,750 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2010 · third_quarter · Food Industry (safety, labeling, etc.)
S. 501: FDA Food Safety and Modernization Act; provisions related to Title I, Improving Capacity to Prevent Food Safety Problems, Section 103: Harard Analysis and risk-based preventative controls.
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 882 - Drug and Device Accountability Act H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2010 · second_quarter · Pharmacy
Generic Biologics, Health Care Reform, Budget Reconcilliation, Implementation of Health Care Reform Bill, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Authorized Generics, Prescription Drug Importation/Re-Importation, 340B Drug Pricing Program, and generic drugs H.R.1427 and S.726 - Promoting Innovation and Access to Life-Saving Medicines Act, all provisions H.R.1548 - Pathway for Biosimilars Act, all provisions H.R.573, all provisions S.501 - Fair Prescription Drug Competition Act, all provisions S.882 - Drug and Device Accountability Act of 2009, Title I Subtitle A, B, C, and D and Title II H.R. 759 - Food and Drug Administration Globalization Act of 2009, Title II S.525, S.1232, and H.R.1298 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act, Title VII - Improving Access to Innovative Medical Therapies; Section 10609 Generic Drug Labeling H.R.3962 - Affordable Health Care for America Act, Title I Subtitle B Part 3 Section 1149A - Payment for Biosimilar Biological Products; Title V Subtitle C Part 2 - Biosimilars H.R.4872 - Reconciliation Bill, Section 1101, Closing the Medicare Prescription Drug "Donut Hole" H.R.4213 - American Jobs and Closing Tax Loopholes Act H.R.4899 - War Supplemental Bill
Client expense: $463,244 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2010 · second_quarter · Copyright/Patent/Trademark
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws International intellectual property issues
Client expense: $4,650,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2010 · second_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; and Congressional oversight issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Food Industry (safety, labeling, etc.)
S. 501: FDA Food Safety and Modernization Act; provisions related to Title I, Improving Capacity to Prevent Food Safety Problems, Section 103: Harard Analysis and risk-based preventative controls.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE